Phosphodiesterase 4 Inhibitors

Compounds that specifically inhibit PHOSPHODIESTERASE 4.

Also Known As:

PDE-4 Inhibitors; PDE4 Inhibitors; Phosphodiesterase Type 4 Inhibitors; 4 Inhibitor, Phosphodiesterase; Inhibitor, PDE-4; Inhibitor, PDE4; Inhibitor, Phosphodiesterase 4; Inhibitors, PDE-4; Inhibitors, PDE4; Inhibitors, Phosphodiesterase 4; PDE 4 Inhibitor; PDE 4 Inhibitors; PDE-4 Inhibitor; PDE4 Inhibitor; Phosphodiesterase 4 Inhibitor; Phosphodiesterase Type 4 Inhibitor

Networked: 931 relevant articles (112 outcomes, 189 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Enzyme Inhibitors: 1659
      - Phosphodiesterase Inhibitors: 1071
        Phosphodiesterase 4 Inhibitors: 931

Experts

1.	Civelli, Maurizio: 13 articles (04/2022 - 02/2014)
2.	Facchinetti, Fabrizio: 12 articles (04/2022 - 02/2014)
3.	Villetti, Gino: 12 articles (04/2022 - 02/2014)
4.	Zhang, Han-Ting: 12 articles (01/2022 - 01/2009)
5.	Giembycz, Mark A: 12 articles (01/2019 - 06/2005)
6.	Lahu, Gezim: 12 articles (01/2018 - 03/2007)
7.	Wang, Haitao: 11 articles (07/2022 - 01/2014)
8.	Xu, Jiangping: 11 articles (07/2022 - 01/2014)
9.	Singh, Dave: 11 articles (11/2021 - 03/2010)
10.	Xu, Jiang-Ping: 10 articles (01/2022 - 07/2012)

Related Diseases

1.	Chronic Obstructive Pulmonary Disease (COPD) 08/01/2005 - "Together with their potent anti-inflammatory properties, the potentially enhanced airway mucociliary clearance from CFTR activation may have contributed to the efficacy of PDE4 inhibitors in COPD and asthmatic patients. " 05/11/2011 - " with a PDE(4) inhibitor was associated with a significant improvement in FEV(1)over the trial period compared with placebo (MD 45.59 mL; 95% confidence interval (CI) 39.15 to 52.03), regardless of COPD severity or concomitant COPD treatment. " 08/01/2011 - "[Are phosphodiesterase 4 inhibitors really helpful in COPD?]." 01/01/2021 - "The T lymphocyte is a major cell type present in the inflammatory infiltrate in the airway wall in patients with chronic obstructive pulmonary disease (COPD), and a previous study found that treatment with a PDE4 inhibitor significantly suppressed T cell proliferation. " 01/01/2017 - "Longer-term trials are needed to determine whether or not PDE4 inhibitors modify FEV1 decline, hospitalisation or mortality in COPD."
2.	Asthma (Bronchial Asthma) 07/01/2022 - "Despite its proven efficacy in other respiratory disorders, including asthma, no other PDE4 inhibitor is approved for respiratory pathologies. " 05/01/2009 - "Further study of PDE4D variants might lead to improved understanding of the role of PDE4D in asthma pathophysiology and the efficacy of PDE4 inhibitor medications." 03/01/2009 - "Over a 14-day treatment period, the oral PDE4 inhibitor MK-0359 improved lower airway function, symptoms and rescue medication use in chronic asthma, although at the expense of gastrointestinal adverse experiences. " 03/01/2009 - "This study evaluated the efficacy and safety of MK-0359, a selective and potent oral PDE4 inhibitor, in chronic asthma. " 03/01/2009 - "Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma."
3.	Psoriasis (Pustulosis Palmaris et Plantaris) 01/01/2023 - "The objective of this study was to compare the efficacy and safety of oral small-molecule drugs, including TYK2 and PDE4 inhibitors, in treating moderate-to-severe plaque psoriasis. " 01/01/2022 - "Efficacy and safety profile of phosphodiesterase 4 inhibitor in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials." 03/01/2019 - "As systemic PDE4 inhibition has also been used with success in psoriasis, clinical trials are underway to determine the utility of topical PDE4 inhibitors in these patients. " 05/01/2013 - "Trial watch: PDE4 inhibitor leads wave of target-specific oral psoriasis drugs." 01/01/2023 - "However, no previous articles evaluated the benefit and risk profile of TYK2 and PDE4 inhibitors in psoriasis. "
4.	Atopic Dermatitis (Atopic Eczema) 10/11/2023 - "Phosphodiesterase 4 inhibitors have been approved for the treatment of atopic dermatitis. " 02/01/2023 - "HY072808 is a novel phosphodiesterase 4 inhibitor currently under clinical development to treat atopic dermatitis. " 01/01/2022 - "Safety Profile and Tolerability of Topical Phosphodiesterase 4 Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis." 03/05/2021 - "In this work, a series of structurally novel benzoxaborole derivatives were designed, synthesized and biologically evaluated as PDE4 inhibitors for battling atopic dermatitis (AD). " 03/05/2021 - "Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis."
5.	Inflammation (Inflammations) 04/01/1999 - "In the present study, we compared the activity of five PDE4 inhibitors in vitro and against trafficking of (111)In-eosinophils in cutaneous inflammation in the guinea-pig. " 12/01/2017 - "These findings underline the significance of the increased MKP-1 expression and decreased JNK phosphorylation associated with the downregulated expression of mPGES-1 by PDE4 inhibitors in inflammation." 12/05/2015 - "We hypothesized that delivery of a dry powdered PDE4 inhibitor by inhalation would minimize systemic absorption and enable local PDE4 inhibition to suppress inflammation within the lung. " 01/01/2014 - "PDE4 inhibitors can suppress inflammation by increasing the concentration of cAMP in inflammatory cells. " 07/01/2013 - "Local delivery of a PDE4 inhibitor to the site of inflammation may overcome these issues. "

Related Drugs and Biologics

1.	Roflumilast
2.	apremilast
3.	Type 4 Cyclic Nucleotide Phosphodiesterases
4.	Rolipram
5.	Phosphoric Diester Hydrolases (Phosphodiesterases)
6.	Cilomilast
7.	Phosphodiesterase 4 Inhibitors
8.	crisaborole
9.	methyl 4- (((3- (6,7- dimethoxy- 2- (methylamino)quinazolin- 4- yl)phenyl)amino)carbonyl)benzoate
10.	Smoke

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Aftercare (After-Treatment)
4.	Anesthesia
5.	Oral Administration